View Financial HealthActive Fine Chemicals 配当と自社株買い配当金 基準チェック /06Active Fine Chemicals配当を支払う会社であり、現在の利回りは0.37%です。主要情報0.4%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).お知らせ • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).すべての更新を表示Recent updatesNew Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (৳1.78b market cap, or US$14.5m).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • May 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 20% over the past year. Minor Risk Market cap is less than US$100m (৳3.77b market cap, or US$32.1m).New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).New Risk • Dec 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).お知らせ • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.00, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.7% over the past three years.Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).Reported Earnings • Jun 24Third quarter 2021 earnings released: EPS ৳0.024 (vs ৳0.19 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ৳510.4m (up 55% from 3Q 2020). Net income: ৳5.86m (down 87% from 3Q 2020). Profit margin: 1.1% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Dec 28New 90-day high: ৳16.90The company is up 1.0% from its price of ৳16.80 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: ৳13.90The company is down 1.0% from its price of ৳14.00 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.決済の安定と成長配当データの取得安定した配当: ACTIVEFINEの配当金支払いは、過去10年間 変動性 が高かった。増加する配当: ACTIVEFINEの配当金支払額は過去10年間減少しています。配当利回り対市場Active Fine Chemicals 配当利回り対市場ACTIVEFINE 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ACTIVEFINE)0.4%市場下位25% (BD)0.7%市場トップ25% (BD)3.4%業界平均 (Pharmaceuticals)3.6%アナリスト予想 (ACTIVEFINE) (最長3年)n/a注目すべき配当: ACTIVEFINEの配当金 ( 0.37% ) はBD市場の配当金支払者の下位 25% ( 0.68% ) と比べると目立ったものではありません。高配当: ACTIVEFINEの配当金 ( 0.37% ) はBD市場の配当金支払者の上位 25% ( 3.36% ) と比較すると低いです。株主への利益配当収益カバレッジ: ACTIVEFINEの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ACTIVEFINEの 現金配当性向 を計算して、配当金の支払いがキャッシュフローでカバーされているかどうかを判断するにはデータが不十分です。高配当企業の発掘7D1Y7D1Y7D1YBD 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 06:17終値2026/07/16 00:00収益2023/03/31年間収益2022/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Active Fine Chemicals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
お知らせ • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.
Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).
New Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (৳1.78b market cap, or US$14.5m).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • May 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 20% over the past year. Minor Risk Market cap is less than US$100m (৳3.77b market cap, or US$32.1m).
New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).
New Risk • Dec 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023
Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
お知らせ • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.00, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.7% over the past three years.
Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).
Reported Earnings • Jun 24Third quarter 2021 earnings released: EPS ৳0.024 (vs ৳0.19 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ৳510.4m (up 55% from 3Q 2020). Net income: ৳5.86m (down 87% from 3Q 2020). Profit margin: 1.1% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Dec 28New 90-day high: ৳16.90The company is up 1.0% from its price of ৳16.80 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: ৳13.90The company is down 1.0% from its price of ৳14.00 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.